Inefficacy of selegiline in treatment of canine pituitary-dependent hyper-adrenocorticism

Braddock, J.A., Church, D.B., Robertson, I.D.ORCID: 0000-0002-4255-4752 and Watson, A.D.J. (2004) Inefficacy of selegiline in treatment of canine pituitary-dependent hyper-adrenocorticism. Australian Veterinary Journal, 82 (5). pp. 272-277.

Abstract

Objective: To evaluate selegiline, a monoamine oxidase-B inhibitor, for treating dogs with pituitary-dependent hyperadrenocorticism. Design: Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at The University Veterinary Centre, Sydney, from September 1999 to July 2001. Procedure: Eleven dogs with pituitary-dependent hyperadrenocorticism treated with selegiline were monitored at days 10, 30 and 90 by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and client questionnaire. Endogenous adrenocorticotropic hormone measurements were also performed on most dogs on days 0 and 90. Results: No dog treated with selegiline had satisfactory control of disease. Conclusion: Selegiline administration was safe and free of side-effects at the doses used, but did not satisfactorily control disease in pituitary-dependent hyperadrenocorticism affected dogs.

Item Type:	Journal Article
Murdoch Affiliation(s):	School of Veterinary and Biomedical Sciences
Publisher:	Wiley-Blackwell
URI:	http://researchrepository.murdoch.edu.au/id/eprint/16397

Item Control Page